Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NEJM

 Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NEJM

Shots:

  • The P-III REACH3 study involves the safety & efficacy of ruxolitinib vs BAT in patients with steroid-refractory chronic GVHD
  • The study showed improvements in 1EPs i.e ORR (49.7% vs 25.6%) & BOR (76.4% vs 60.4%) @24wks. & also showed the improvements in 2EPs i.e patients achieved longer FFS than BAT, m-FFS (not reached vs. 5.7mos.); improvements in self-reported symptoms (24.2% vs 11.0%), no new safety signals were observed
  • The new subgroup analysis showed higher ORR for Jakavi-treated patients regardless of individual organs involved at baseline. Regulatory submissions are currently ongoing for acute & chronic GvHD outside the US

Click here to read full press release/ article | Ref: Novartis | Image: Clinical Trials Arena

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post